Cibacen 10mg Film Coated Tablet
Product Information *
Company:
Mylan IRE Healthcare LimitedStatus:
No Recent UpdateActive Ingredients :
*Additional information is available upon request
Legal Category:
Product subject to medical prescription which may be renewed (B)
When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.
Updated on 30 July 2018
File name
ie-pl-cibacen-10mg-mahtransfer-clean_1532956511.pdf
Reasons for updating
- New PIL for new product
Updated on 30 July 2018
File name
ie-spc-cibacen-10mg-mahtransfer-clean_1532956640.pdf
Reasons for updating
- Change to section 7 - Marketing authorisation holder
- Change to section 8 - Marketing authorisation number(s)
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 03 January 2017
Reasons for updating
- New SPC for new product
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 03 January 2017
Reasons for updating
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
In section 10: date of revision has changed
Updated on 03 January 2017
Reasons for updating
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 10 - Date of revision of the text
Free text change information supplied by the pharmaceutical company
In section 10: date of revision has changed
Updated on 14 October 2016
Reasons for updating
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.9 - Overdose
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
In section 4.4: Information regarding ciclosporin and heparin has been added. Information regarding mTOR inhibitors and NSAIDs has been added.
In section 4.9: Information to overdose has been added.
In section 10: Date of revision changed.
Updated on 14 October 2016
Reasons for updating
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.9 - Overdose
- Change to section 10 - Date of revision of the text
Free text change information supplied by the pharmaceutical company
In section 4.4: Information regarding ciclosporin and heparin has been added. Information regarding mTOR inhibitors and NSAIDs has been added.
In section 4.9: Information to overdose has been added.
In section 10: Date of revision changed.
Updated on 05 January 2015
Reasons for updating
- Change to section 4.1 - Therapeutic indications
- Change to section 4.2 - Posology and method of administration
- Change to section 4.3 - Contraindications
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 10 - Date of revision of the text
Free text change information supplied by the pharmaceutical company
In section 4.1: Text is added to refer to other sections
In section 4.2: Text is added to refer to other sections. Reference has changed to elderly patients
In section 4.3: Concomitant use with aliskiren-containing products has been added as a contraindication
In section 4.4: Information regarding dual blockade of the renin-angiotensin-aldosterone system has been added
In section 4.5: Information regarding clinical trial data and dual blockade of the renin-angiotensin-aldosterone system has been added
In section 4.8: Statement regarding adverse reporting has been added
In section 5.1: Text regarding particular clinical trials ONTARGET and VA NEPHRON-D has been added. Information regarding ALTITUDE study has been added.
In section 10: date of revision has changed
Updated on 05 January 2015
Reasons for updating
- Change to section 4.1 - Therapeutic indications
- Change to section 4.2 - Posology and method of administration
- Change to section 4.3 - Contraindications
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
In section 4.1: Text is added to refer to other sections
In section 4.2: Text is added to refer to other sections. Reference has changed to elderly patients
In section 4.3: Concomitant use with aliskiren-containing products has been added as a contraindication
In section 4.4: Information regarding dual blockade of the renin-angiotensin-aldosterone system has been added
In section 4.5: Information regarding clinical trial data and dual blockade of the renin-angiotensin-aldosterone system has been added
In section 4.8: Statement regarding adverse reporting has been added
In section 5.1: Text regarding particular clinical trials ONTARGET and VA NEPHRON-D has been added. Information regarding ALTITUDE study has been added.
In section 10: date of revision has changed
Updated on 05 December 2012
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.8 - Undesirable effects
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 10 - Date of revision of the text
Free text change information supplied by the pharmaceutical company
· In section 4.4: a short warning regarding angioedema has been added
· In section 4.5: an additional warning regarding the interaction of gold has been added
· In section 4.8: there has been several changes made to the undesirable effects
· In section 5.1: an additional statement has been added relating to the use of Cibacen in CHF patients
· In section 10: the date of revision has been changed to November 2012
Updated on 05 December 2012
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.8 - Undesirable effects
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
· In section 4.4: a short warning regarding angioedema has been added
· In section 4.5: an additional warning regarding the interaction of gold has been added
· In section 4.8: there has been several changes made to the undesirable effects
· In section 5.1: an additional statement has been added relating to the use of Cibacen in CHF patients
· In section 10: the date of revision has been changed to November 2012
Updated on 02 November 2011
Reasons for updating
- Change to section 4.3 - Contraindications
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.6 - Pregnancy and lactation
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 10 - Date of revision of the text
Free text change information supplied by the pharmaceutical company
In section 4.4; warnings against the use of ACE inhibitors in pregnancy have been added
In section 4.6; the section has been restructed to include ACE inhibitor warnings in pregnancy and lactation
In section 5.2; additional information regarding lactation has been added
In section 10; the date of revision has changed
Updated on 02 November 2011
Reasons for updating
- Change to section 4.3 - Contraindications
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.6 - Pregnancy and lactation
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
In section 4.4; warnings against the use of ACE inhibitors in pregnancy have been added
In section 4.6; the section has been restructed to include ACE inhibitor warnings in pregnancy and lactation
In section 5.2; additional information regarding lactation has been added
In section 10; the date of revision has changed
Updated on 18 March 2011
Reasons for updating
- Change to section 7 - Marketing authorisation holder
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
In section 10: the date of revison has changed to
Updated on 18 March 2011
Reasons for updating
- Change to section 7 - Marketing authorisation holder
- Change to section 10 - Date of revision of the text
Free text change information supplied by the pharmaceutical company
In section 10: the date of revison has changed to
Updated on 17 January 2011
Reasons for updating
- Change to section 3 - Pharmaceutical form
- Change to section 4.2 - Posology and method of administration
- Change to section 4.8 - Undesirable effects
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 5.3 - Preclinical safety data
- Change to section 10 - Date of revision of the text
Free text change information supplied by the pharmaceutical company
In section 4.2: additional information regarding the dosage to children aged 7-16 years has beeen added
In section 4.8: Addition of text regarding the toleration of paedriatric patients and other information
In section 5.1: Information added regarding a clinical trail of 107 paediatric patients aged 7-16 years
In section 5.2:addition of information regarding the elimination of product in paediatric patients
In section 5.3: Addition of text that no non-clinincal studies have been conducted with the purpose of investigating potential juvenile toxcity of benazepril HCL
In section 10: Revision of text changed
Updated on 17 January 2011
Reasons for updating
- Change to section 3 - Pharmaceutical form
- Change to section 4.2 - Posology and method of administration
- Change to section 4.8 - Undesirable effects
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 5.3 - Preclinical safety data
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
In section 4.2: additional information regarding the dosage to children aged 7-16 years has beeen added
In section 4.8: Addition of text regarding the toleration of paedriatric patients and other information
In section 5.1: Information added regarding a clinical trail of 107 paediatric patients aged 7-16 years
In section 5.2:addition of information regarding the elimination of product in paediatric patients
In section 5.3: Addition of text that no non-clinincal studies have been conducted with the purpose of investigating potential juvenile toxcity of benazepril HCL
In section 10: Revision of text changed
Updated on 04 October 2007
Reasons for updating
- Change to marketing authorisation holder
Legal category:Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
Novartis Pharmaceuticals UK Limited
Frimley Business Park
Frimley
Camberley
Surrey GU16 7SR
Meda Health Sales Ireland Ltd
Office 10,
Dunboyne
Updated on 04 October 2007
Reasons for updating
- Change to marketing authorisation holder
Free text change information supplied by the pharmaceutical company
Novartis Pharmaceuticals UK Limited
Frimley Business Park
Frimley
Camberley
Surrey GU16 7SR
Meda Health Sales Ireland Ltd
Office 10,
Dunboyne
Updated on 05 August 2005
Reasons for updating
- Change to section 6.1 - List of excipients
- Change to section 10 - Date of revision of the text
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 05 August 2005
Reasons for updating
- Change to section 6.1 - List of excipients
- Change to section 10 - Date of revision of the text
Updated on 04 February 2005
Reasons for updating
- New SPC for medicines.ie
Updated on 04 February 2005
Reasons for updating
- New SPC for medicines.ie
Legal category:Product subject to medical prescription which may be renewed (B)